doi: 10.1093/bja/aex191 Review Article

# REVIEW ARTICLE

# Efficacy of perineural *vs* systemic dexamethasone to prolong analgesia after peripheral nerve block: a systematic review and meta-analysis

M. Baeriswyl<sup>1</sup>, K. R. Kirkham<sup>2</sup>, A. Jacot-Guillarmod<sup>1</sup> and E. Albrecht<sup>1,\*</sup>

<sup>1</sup>Department of Anaesthesia, Lausanne University Hospital, Lausanne, Switzerland and <sup>2</sup>Department of Anaesthesia, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada

\*Corresponding author. Department of Anaesthesia, Lausanne University Hospital, Rue du Bugnon 46, BH 05.311, 1011 Lausanne, Switzerland. E-mail: eric.albrecht@chuv.ch

## Abstract

Perineural dexamethasone has gained popularity in regional anaesthesia to prolong the duration of analgesia, but its advantage over systemic administration is disputed. The objective of this meta-analysis was to compare the analgesic efficacy of both routes of administration during peripheral nerve block. The methodology followed the PRISMA statement guidelines. The primary outcome was the duration of analgesia analysed according to the type of local anaesthetic administered (bupivacaine or ropivacaine). Secondary outcomes included cumulative opioid consumption in morphine i.v. equivalents, pain scores, and complication rates (neurological complications, infection, or hyperglycaemia). Eleven controlled trials, including 914 patients, were identified. The duration of analgesia was significantly increased with perineural dexamethasone vs systemic dexamethasone by a mean difference of 3 h [95% confidence interval (CI): 1.4, 4.5 h; P=0.0001]. Subgroup analysis revealed that the duration of analgesia was increased by 21% with bupivacaine (mean difference: 4.0 h; 95% CI: 2.8, 5.2 h; P<0.00001) and 12% with ropivacaine (mean difference: 2.0 h; 95% CI: -0.5, 4.5 h; P=0.11). The quality of evidence for our primary outcome was moderate according to the GRADE system. There were no significant differences in other secondary outcomes. No neurological complications or infections were reported. Glucose concentrations were not increased when dexamethasone was injected systemically, but this outcome was reported by only two trials. There is, therefore, moderate evidence that perineural dexamethasone combined with bupivacaine, but not ropivacaine, slightly prolongs the duration of analgesia, without an impact on other pain-related outcomes, when compared with systemic dexamethasone. Injection of perineural dexamethasone should be cautiously balanced in light of the off-label indication for this route of administration.

Key words: analgesia; anesthetics, local; dexamethasone; nerve block; pain, postoperative

Multiple adjuncts to local anaesthetics, such as neostigmine, tramadol, or clonidine, have been examined for their potential to prolong analgesia after regional nerve blocks, but with disappointing results.<sup>1</sup> Perineural dexamethasone was first explored clinically >12 yr ago,<sup>2</sup> followed by a myriad of clinical trials.

Recently, a meta-analysis concluded that perineural dexamethasone, compared with placebo, prolonged the duration of analgesia by >8 h, when combined with long-acting local anaesthetics, suggesting that patients could benefit from a pain-free postoperative night.<sup>3</sup> The mechanism of action for this

© The Author 2017. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com

prolongation of block is not fully understood, but suggested possibilities include decreased nociceptive C-fibre activity via a direct effect on glucocorticoid receptors,<sup>4</sup> a direct effect on inhibitory potassium channels,<sup>5</sup> a local vasoconstrictive effect,<sup>6</sup> or a systemic anti-inflammatory effect.<sup>7</sup>

Despite the evident clinical benefit, perineural dexamethasone remains an off-label route of administration. An alternative choice of dexamethasone i.v. has likewise been explored, which at moderate doses offers the potential for a systemic anti-inflammatory effect.<sup>8</sup> In a randomized controlled trial, Desmet and colleagues<sup>9</sup> explored both routes of administration and concluded that they offer an equivalent prolongation of analgesia. This early conclusion has been disputed in subsequent trials,<sup>3 10 11</sup> with some authors concluding that additional rigorous assessment of both routes of administration was warranted.  $^{\rm 12}$ 

The objectives of this meta-analysis were to compare the analgesic efficacy and side-effects of perineural *vs* systemic dexamethasone administration as an adjunct to local anaesthetic for peripheral nerve block in adult patients.

#### Methods

#### Literature search and inclusion criteria

This investigation followed the recommended process described in the 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses' (PRISMA) statement.<sup>13</sup> The authors





Fig 2 Cochrane collaboration risk of bias summary: evaluation of bias risk items for each included study. Green circle, low risk of bias; red circle, high risk of bias; yellow circle, unclear risk of bias.

**A** 

?

Ŧ

 2

Fredrickson et al., 2013 (ref 26)

Kawanishi et al., 2014 (ref 10)

Leurcharusmee et al., 2016 (ref 11)

Rahangdale et al., 2014 (ref 27)

Rosenfeld et al., 2014 (ref 28)

YaDeau et al., 2015 (ref 29)

searched electronic databases, including the following: Medline (until January 2017), PubMed (until January 2017), Excerpta Medica database, Embase (until January 2017), and the Cochrane Central Register of Controlled Clinical Trials (until January 2017), and applied the following population search terms: Anaesthetic technique OR Anesthetic technique OR Anaesthesia conduction OR Anesthesia conduction OR Local anaesthetics OR Local anesthetics OR Nerve block OR Peripheral nerve block OR Regional anaesthesia OR Regional anesthesia. These search results were combined with Dexamethasone OR Glucocorticoids OR Steroids. Results were further limited by combining with Clinical trials OR Random allocation OR Therapeutic use. The following words were searched as keywords: Anaesth\*, Anesth\*, Nerve\*, Dexamethas\*, Glucocort\*, Steroid\*, Clinical\*, Random\*, Trial\*. The results of this search strategy were limited to randomized controlled trials and humans. No age or language limits were placed on the search. Finally, the references of all articles retrieved from the search were manually scrutinized for any relevant trials not identified using the strategy described above, and Google Scholar<sup>™</sup> was examined for any additional publications.

## Population

The meta-analysis addresses male and female patients undergoing any surgical operation with a regional nerve block.

#### Intervention and comparator

Only trials comparing perineural dexamethasone and local anaesthetics with systemic (i.v. or i.m.) dexamethasone and perineural local anaesthetics alone for peripheral nerve block were included in the present meta-analysis.

#### Outcomes

The specific outcomes sought from each article were derived according to our standard approach, which we described in a previous meta-analysis on acute postoperative pain.<sup>14</sup> The primary outcome was the duration of analgesia or duration of sensory block, defined as the time interval between block performance or onset time of sensory block and the time of first analgesic request or initial pain report. Secondary acute pain-related outcomes were as follows: cumulative morphine i.v. consumption equivalent on postoperative day 1; any pain score recorded at rest and on movement in the early postoperative days 1 and 2; rates of postoperative nausea and vomiting within the first 24h after surgery; and patient satisfaction. Secondary side-effect-related outcomes were rates of neurological complication, infection, and hyperglycaemia.

## **Trial characteristics**

Extracted trial characteristics included the following: type of surgery; type of regional block; concentration and volume of local anaesthetics injected; dose of dexamethasone; and use and type of multimodal analgesia.

#### Rating of the studies

The quality of the research methodology of each randomized trial was assessed following the Cochrane Collaboration's Risk of Bias Tool for randomized controlled trials.<sup>15</sup> Two authors (A.J.-G. and K.R.K.) independently screened, reviewed, and scored the items for each trial using this method and extracted data for the analyses. Disagreements with scoring or extracted data were resolved through discussion with a third author (E.A.).

#### Data extraction

The source study text, tables, or graphs were used to extract the mean values, SD or SEM, 95% confidence intervals (CI), number of events, and total number of participants. The authors of trials that failed to report the sample size or results as a mean value and sD or SEM or 95% CI were requested twice by mail to give the missing or raw data. If no reply was obtained, the median and interquartile range were used for mean and sD approximations, as follows: the mean was estimated as equivalent to the median and the sD was approximated to be the interquartile range divided by 1.35.16 All opioids were converted into equi-analgesic doses of morphine i.v. for analysis (morphine 10 mg i.v.=morphine 30 mg p.o.=hydro morphone 1.5 mg i.v.=hydromorphone 7.5 mg p.o.=pethidine 75 mg i.v.=oxycodone 20 mg p.o.=tramadol 100 mg i.v.).<sup>17</sup> Pain scores and patient satisfaction scores reported as visual, verbal, or numerical rating scales were converted to a standardized 0-10 analog scale for quantitative evaluations. Finally, we rated the

Reference	Group (n)	Local anaesthetic	Regional nerve block	Regional technique	Surgery	Other anaesthesia	Postoperative analgesia	Primary outcome
Abdallah <i>e</i> t al. (2015) <sup>22</sup>	Perineural dexamethasone 8 mg (25), dexamethasone 8 mg i.v. (25)	Bupivacaine 0.5%, 30 ml	Supraclavicular brachial plexus block	Ultrasound	Distal upper limb surgery	I.V. sedation with propofol or midazolam	Fentanyl, paraceta- mol, codeine, oxycodone	Duration of analgesia
Aliste et al. (2017) <sup>23</sup>	Perineural dexamethasone 8 mg (75), dexamethasone 8 mg i.v. (75)	Lidocaine 1% plus bupivacaine 0.25% plus epinephrine 5 µg ml <sup>-1</sup> , 30 ml	Axillary brachial plexus block	Ultrasound	Distal upper limb surgery	I.V. sedation with propofol	Not specified	Duration of motor block
Chun et al. (2016) <sup>24</sup>	Perineural dexamethasone 5 mg (50), dexamethasone 5 mg i.v. (49)	Ropivacaine 0.75%, 8 ml	Interscalene bra- chial plexus block	Ultrasound	Arthroscopic shoulder surgery	General anaesthesia	Ketorolac, tramadol	Duration of analgesia
Dawson <i>et a</i> l. (2016) <sup>25</sup>	Perineural dexamethasone 8 mg (30), dexamethasone 8 mg i.v. (30)	Ropivacaine 0.75%, 20 ml	Ankle block	Ultrasound	Foot surgery	None	Paracetamol, oxyco- done, tramadol	Duration of analgesia
Desmet <i>e</i> t al. (2013) <sup>9</sup>	Perineural dexamethasone 10 mg (49), dexamethasone 10 mg i.v. (49)	Ropivacaine 0.5%, 30 ml	Interscalene bra- chial plexus block	Nerve stimulation	Arthroscopic shoulder surgery	General anaesthesia	Paracetamol, diclofe- nac, piritramide	Duration of analgesia
Fredrickson <i>et al.</i> (2013) <sup>26</sup>	Perineural dexamethasone 10 mg (33), dexamethasone 10 mg i.m. (33)	Bupivacaine 0.5%, 30 ml	Sciatic nerve block (popliteal approach) plus saphenous nerve block	Ultrasound	Ankle, hind- and midfoot surgery	General anaesthesia	I.V. morphine, parace- tamol, diclofenac, tramadol	Proportion of patients report- ing pain at 48 h
Fredrickson et al. (2013) <sup>26</sup>	Perineural dexamethasone 8 mg (28), dexamethasone 8 mg i.m. (32)	Bupivacaine 0.5%, 30 ml	Ankle block	Ultrasound	Forefoot surgery	General anaesthesia	I.V. morphine, parace- tamol, diclofenac, tramadol	Proportion of patients report- ing pain at 48 h
Kawanishi et al. (2014) <sup>10</sup>	Perineural dexamethasone 4 mg (12), dexamethasone 4 mg i.v. (10)	Ropivacaine 0.75%, 20 ml	Interscalene bra- chial plexus block	Ultrasound	Arthroscopic shoulder surgery	General anaesthesia	Flurbiprofen, loxoprofen	Duration of analgesia
Leurcharusm- ee <i>et a</i> l. (2016) <sup>11</sup>	Permeural dexamethasone 5 mg (61), dexamethasone 5 mg i.v. (62)	Lıdocame 1% plus bupivacaine 0.25% plus epinephrine 2.5 µg ml <sup>-1</sup> , 35 ml	Infraclavıcular brachial plexus block	Ultrasound	Dıstal upper limb surgery	I.V. sedation with propofol	Not specified	Duration of motor block
Rahangdale et al. (2014) <sup>27</sup>	Perineural dexamethasone 8 mg (27), dexamethasone 8 mg i.v. (23)	Bupivacaine 0.5% plus epinephrine 3.3 µg ml <sup>-1</sup> , 0.45 ml kg <sup>-1</sup>	Sciatic nerve block (infragluteal approach)	Ultrasound	Ankle and foot surgery	I.V. sedation with propofol	Paracetamol, hydrocodone	Quality of recovery questionnaire (QoR-40) score
Rosenfeld et al. (2016) <sup>28</sup>	Perineural dexamethasone 8 mg (42), dexamethasone 8 mg i.v. (37)	Ropivacaine 0.5%, 28 ml	Interscalene bra- chial plexus block	Ultrasound	Arthroscopic and open shoulder surgery	General anaesthesia	Morphine, hydromor- phone, hydroco- done, oxycodone, ketorolac	Duration of analgesia
YaDeau <i>et a</i> l. (2016) <sup>29</sup>	Perineural dexamethasone 4 mg (28), dexamethasone 4 mg i.v. (27)	Bupivacaine 0.25%, 35 ml	Sciatic nerve block (popliteal approach, 25 ml) plus adductor canal block (10 ml)	Ultrasound	Ankle and foot surgery	Neuraxial anaes- thesia plus i.v. sedation with propofol or midazolam	Paracetamol, meloxi- cam, pregabalin, oxycodone	Pain on movement at 24 h postoperative

quality of evidence for each outcome following the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Working Group system.<sup>18</sup>

#### Statistical analysis

Meta-analyses were performed with the assistance of Review Manager software (RevMan version 5.3.5; The Cochrane Collaboration 2014, The Nordic Cochrane Centre, Copenhagen, Denmark). This software estimates the weighted mean differences for continuous data and risk ratio for categorical data between groups, with an overall estimate of the pooled effect. A metaanalysis was conducted only if two or more trials reported the outcome of interest. The coefficient I<sup>2</sup> was used to evaluate heterogeneity with predetermined thresholds for low (25-49%), moderate (50-74%), and high (>75%) levels.<sup>19</sup> A random-effects model was applied in the event of moderate or high heterogeneity; otherwise, a fixed-effects model was used. Our primary outcome, duration of analgesia, was analysed in subgroups according to the type of local anaesthetic (bupivacaine or ropivacaine) to account for heterogeneity. The likelihood of publication bias was assessed by drawing a funnel plot of the standard error of the mean difference in duration of the analgesia (y-axis) as a function of the mean difference in duration of analgesia (x-axis) and confirmed with Duval and Tweedie's trim and fill test.<sup>20</sup> This assessment was performed using Comprehensive Meta-analysis Version 2 software (Biostat, Englewood, NJ, USA). Finally, a trial sequential analysis was executed on the duration of analgesia combined with bupivacaine or ropivacaine to confirm whether firm evidence was reached or not (TSA software version 0.9.5.5 Beta; Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark).<sup>21</sup> Results are presented as the mean difference or relative risk (RR) with 95% confidence interval (CI). A two-sided P-value <0.05 was considered significant.

#### Results

Of the 488 trials identified from the literature search strategy, 11 met the inclusion criteria, representing a total of 914 patients (Fig. 1).  $^{9-11}$  <sup>22–29</sup>

According to our assessment using the Cochrane Collaboration Risk of Bias tool (Fig. 2), the majority of trials had a low risk of bias. Attempts were made to contact the authors of seven studies, <sup>9</sup> <sup>10</sup> <sup>22</sup> <sup>25–28</sup> and five provided the additional data requested. <sup>9</sup> <sup>22</sup> <sup>25</sup> <sup>27</sup> <sup>28</sup> Data were approximated from the median and range in three trials. <sup>10</sup> <sup>24</sup> <sup>26</sup>

Table 1 presents the trial characteristics. All trials combined dexamethasone with long-acting local anaesthetics (bupivacaine or ropivacaine) except one that used a sequential injection of dexamethasone first followed by ropivacaine, without needle tip repositioning between injections.<sup>9</sup> All trials administered systemic dexamethasone i.v. except one that used the i.m. route.<sup>26</sup> Studied doses of dexamethasone were 4,<sup>10 29</sup> 5,<sup>11 24</sup> 8,<sup>22 23</sup> 25-28 and 10 mg.<sup>9 26</sup> One publication presented the results of two randomized controlled trials<sup>26</sup>; of note, all patients in these two trials received an additional dose of i.v. dexamethasone 8 mg at the end of surgery.<sup>26</sup>

Upper limb blocks included interscalene, axillary, supraclavicular, and infraclavicular brachial plexus blocks.<sup>9–11</sup> <sup>22–24</sup> <sup>28</sup> Lower limb block sites were the adductor canal, sciatic nerve, and ankle.<sup>25–27</sup> <sup>29</sup> With the exception of one trial where the authors used a nerve stimulator for block localization,<sup>9</sup> all blocks were performed under ultrasound guidance. Regional block was combined with general anaesthesia in five trials<sup>9</sup> <sup>10</sup> <sup>24</sup> <sup>26</sup> <sup>28</sup> and with neuraxial anaesthesia in one.<sup>29</sup>

The duration of analgesia was significantly increased by an average of 17% when dexamethasone was injected perineurally vs systemically (mean difference: 3.0 h; 95% CI: 1.4, 4.5 h; P=0.0001; Fig. 3). Subgroup analysis revealed that the mean duration of analgesia with bupivacaine and systemic dexamethasone was 22.1 h (95% CI: 15.9, 28.3 h), whereas it was 26.8 h with bupivacaine and perineural dexamethasone (95% CI: 19.4, 34.1 h), representing an increase of 21% (mean difference: 4.0 h; 95% CI: 2.8, 5.2 h; P<0.00001). With ropivacaine, the mean duration of analgesia with systemic and perineural dexamethasone was 17.4 h (95% CI: 8.3, 26.6 h) and 19.5 h (95% CI: 9.8, 29.2 h) respectively, representing an increase of 12% that did not reach statistical significance (mean difference: 2.0 h; 95% CI: -0.5, 4.5 h; P=0.11). There was no subgroup difference (P=0.16). The

	Perineur	al adminis	stration	Systemic	adminis	tration		Mean difference	Mean difference
Study or subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, random, 95% CI	IV, random, 95% CI
1.1.1 Bupivacaine									
Abdallah et al., 2015 (ref 22)	25	13.3	25	25	18	25	2.7%	0.00 [-8.77, 8.77]	
Aliste et al., 2017 (ref 23)	21.1	4.6	75	17.1	4.6	75	19.5%	4.00 [2.53, 5.47]	
eurcharusmee et al., 2016 (ref 11)	22.1	8.5	61	18.6	6.7	62	13.6%	3.50 [0.79, 6.21]	
lahangdale et al., 2014 (ref 27)	35.2	7.7	27	29.3	8.9	23	7.4%	5.90 [1.25, 10.55]	
'aDeau et al., 2015 (ref 29)	30.3	17.8	28	20.7	24.5	28	1.7%	9.60 [-1.62, 20.82]	
Subtotal (95% CI)			216			213	45.0%	4.02 [2.79, 5.24]	•
leterogeneity: Tau <sup>2</sup> =0.00; Chi <sup>2</sup> =2.53	3, df=4 ( <i>P</i> =	=0.64); l <sup>2</sup> =	:0%						
est for overall effect: Z=6.42 (P<0.0	0001)								
.1.2 Ropivacaine									
hun et al., 2016 (ref 24)	18	13.5	50	13.5	5.6	49	8.9%	4.50 [0.44, 8.56]	
Dawson et al., 2015 (ref 25)	29.3	10.3	30	25.9	8.2	30	7.3%	3.40 [-1.31, 8.11]	
esmet et al., 2013 (ref 9)	23.8	10.3	49	24.6	11.7	49	8.1%	-0.80 [-5.16, 3.56]	
awanishi et al., 2014 (ref 10)	18	3.3	12	14	1.8	10	16.1%	4.00 [1.82, 6.18]	
osenfeld et al., 2016 (ref 28)	8.4	5.6	42	9.2	5.6	36	14.6%	-0.80 [-3.29, 1.69]	
ubtotal (95% CI)			183			174	55.0%	2.03 [-0.49, 4.54]	►
leterogeneity: Tau <sup>2</sup> =5.09; Chi <sup>2</sup> =11.4	6, df=4 (F	P=0.02); l <sup>2</sup>	=65%						
est for overall effect: Z=1.58 (P=0.1	1)								
otal (95% CI)			399			387	100.0%	2.97 [1.44, 4.51]	•
leterogeneity: Tau <sup>2</sup> =2.58: Chi <sup>2</sup> =18.2	26. df=9 ( <i>F</i>	P=0.03): 1 <sup>2</sup>	=51%						
est for overall effect: 7-3 80 (P-0.0	001)	2.50), 1	2.70						-20 -10 0 10 20
Test for subgroup differences: $Chi^2 - Chi^2$	1 0/ df_1	$(P_{-0.16})$	1 <sup>2</sup> -48 F	0/_					Favours systemic adm. Favours perineural adm.
est for subgroup differences. Off =	1.3 <del>4</del> , ui=1	(7 = 0.10)	, 1 -40.0	/0					

Fig 3 Duration of analgesia according to type of local anaesthetic (bupivacaine us ropivacaine).

Outcomes	References			Ğ	dno			Mean difference	I <sup>2</sup> (%)	P-value	Quality
		Perineural de	kamethason	e	Systemic dex	amethason	e	[95% CI] or relative risk			of evidence
		Mean or n	SD	N	Mean or n	SD	N	[95% CI]			(GRADE)
Cumulative morphine i.v. cons	umption equivalent (mg)										
Postoperative day 1	Abdallah et al. (2015) <sup>22</sup>	4	10	25	4	∞	25	-1 $[-2, 1]$	37	0.29	Moderate
	Dawson et al. (2016) <sup>25</sup>	33	4	30	3	ŝ	30				
	Rahangdale <i>e</i> t al. (2014) <sup>27</sup>	7	7	27	11	7	23				
	Rosenfeld et al. (2016) <sup>28</sup>	12	6	42	17	16	37				
Postoperative day 2	Rahangdale et al. (2014) <sup>27</sup>	10	7	27	00	6	23	2 [-2, 7]	I	0.29	Very low
Pain scores at rest (analog scali	e, 0–10)		2	L		Č	L		Ĺ		
Early postoperative period	Abdallah et al. (2015) Charles et al. (2015)	0.0	0.1	27 0	0.0	0.1 0	57. 07	-0.3 [-0.9, 0.2]	51	0.26	LOW
	CIULIT EL (IL (2016)	2.U	7 7 7	00 4	0.0	0.0	4, c				
	Valuenteia et al. (2016) <sup>-2</sup> Valuent et al 7016) <sup>29</sup>	C.T.	1./ 27	4.7 7 C	2.4	3.U	30				
Postonerative day 1	Abdallah et al (2015) <sup>22</sup>	2.1	, <del>(</del>	رت 70	, c. 1 c.	14	رت 7	-05[-10003	60	0.06	LOW
	Chun et al. $(2016)^{24}$	1.5	1.5	20	2.0	2.2	49		0		:
	Fredrickson et al. (2013) <sup>26</sup>	0.0	1.5	33	0.0	0.7	33				
	(sciatic nerve block)										
	Fredrickson et al. (2013) <sup>26</sup>	0.0	1.5	28	0.0	0.7	32				
	(ankle block)										
	Rahangdale et al. (2014) $^{27}$	0.0	1.5	27	2.5	3.7	24				
	Rosenfeld <i>e</i> t al. (2016) <sup>28</sup>	3.6	2.7	35	3.2	2.4	35				
	YaDeau et al. (2016) <sup>29</sup>	0.8	1.6	28	1.8	2.5	27				
Postoperative day 2	Chun et al. (2016) <sup>24</sup>	1.0	1.5	50	1.0	1.5	49	0.2 [-0.3, 0.6]	0	0.50	Low
	Rahangdale <i>e</i> t al. (2014) <sup>27</sup>	4.0	3.0	27	3.0	3.0	24				
	Rosenfeld <i>e</i> t al. (2016) <sup>28</sup>	3.8	2.2	42	3.7	2.7	36				
	YaDeau et al. (2016) <sup>29</sup>	3.3	2.6	25	2.7	2.7	26				
Pain scores on movement (ana.	log scale, 0–10)										
Early postoperative period	YaDeau et al. (2016) <sup>29</sup>	0.7	2.1	24	0.9	2.2	27	$-0.2 \left[-1.4, 1.0\right]$	I	0.74	Very low
Postoperative day 1	Rahangdale <i>et al.</i> (2014) <sup>27</sup>	0.0	3.0	27	3.5	5.2	24	-1.9 $[-4.7, 1.0]$	78	0.19	Very low
	YaDeau et al. (2016) <sup>23</sup>	1.3	2.1	28	1.9	2.6	27		¢		-
Postoperative day z	vanangaale et al. (2014)	0.0	3./ 0 c	72	0.0	0.0 1	74	0.3 [-0.9, 1.6]	D	YC.U	very low
	Tabeau et al. (2010)	4.3	Q.2	07	5./	J.L	07				
rostoperative nausea and vom	umg Abdallah et al. (2015) <sup>22</sup>	<del>, -</del>		25	<del></del>		25	0.88 [0.37, 2,12]	C	0.78	I.o.w
	Dawson et al. (2016) <sup>25</sup>	- 0		30	- 0		30		,		:
	Kawanishi et al. (2014) <sup>10</sup>	0		12	1 1		10				
	Rosenfeld <i>et a</i> l. (2016) <sup>28</sup>			42	0		37				
	YaDeau et al. (2016) <sup>29</sup>	- LJ		26	9		27				
Patient satisfaction (at 24 h)											
	Abdallah et al. (2015) <sup>22</sup>	9.0	2.7	25	9.0	2.4	25	0 [-0.4, 0.3]	0	0.96	Low
	Rahangdale <i>et a</i> l. (2014) <sup>27</sup>	10.0	0.0	27	10.0	0.0	23				
	Rosenfeld <i>et al.</i> $(2016)^{28}$	7.8	2.7	34	7.9	2.6	28				
	VaDanii at al /2016/29	10.0	r 0	c	007	۲ 0	10				

tcome Referen	lce		Gro	dn		Relative risk	I <sup>2</sup> (%)	P-value	Quality
		Perineural de	xamethasone	Systemic de	gamethasone	[95% CI]			of evidence
		u	N	и	N				(GRADE)
urological complic:	ation								
Abdalla	ih et al. (2015) <sup>22</sup>	0	25	0	25	1.22 [0.65, 2.29]	0	0.53	Moderate
Chun et	t al. (2016) <sup>24</sup>	1	50	2	49				
Fredric	kson et al. (2013) <sup>26</sup> (sciatic nerve block)	6	33	9	33				
Fredric	kson et al. (2013) <sup>26</sup> (ankle block)	Ŋ	28	4	32				
Leurch	arusmee et al. (2016) <sup>11</sup>	0	61	0	62				
Rahang	$dale et al. (2014)^{27}$	2	27	2	24				
YaDear	1 et al. (2016) <sup>29</sup>	1	28	1	27				
e of infection									
Desmei	t <i>e</i> t <i>a</i> l. (2013) <sup>9</sup>	0	49	0	49	0.29 [0.01, 7.02]	I	0.45	Low
Leurch	arusmee et al. (2016) <sup>11</sup>	0	61	0	62				
Rosenfe	eld et al. (2016) <sup>28</sup>	0	42	1	37				

trial sequential analysis indicated that firm evidence was reached and that perineural was superior to systemic dexamethasone when combined with bupivacaine (Supplementary Fig. S1). With ropivacaine, the finding of equivalence between both routes of administration remains underpowered, and a total of 1124 patients would be needed before suggesting a definitive conclusion (Supplementary Fig. S2). The quality of evidence for our primary outcome was moderate according to the GRADE system. With regard to the funnel plots for our primary outcome (Supplementary Fig. S3), the Duval and Tweedie's trim and fill test revealed the point estimates for the combined studies to be 0.40 (95% CI: 0.15, 0.67), suggesting an absence of publication bias.

There were no significant differences in the other secondary pain outcomes (Table 2) or side-effects (Table 3). Blood glucose concentrations were not increased when dexamethasone was injected systematically compared with the perineural route, but this outcome was reported by only two trials (mean difference  $-0.8 \text{ mmol litre}^{-1}$ ; 95% CI: -1.8, 0.3 mmol litre $^{-1}$ ; I<sup>2</sup>=89%; P=0.17; quality of evidence: very low).<sup>9 24</sup>

## Discussion

This systematic review and meta-analysis compared the analgesic efficacy and side-effects of perineural vs systemic administration of dexamethasone as an adjunct to local anaesthetic for peripheral nerve block in adult patients. Based on 11 randomized controlled trials, including a total of 914 patients, we showed that perineural dexamethasone slightly prolongs duration of analgesia without an impact on other pain-related outcomes and without side-effects. The subgroup analysis demonstrated that the increased duration of analgesia was statistically significant with bupivacaine but not with ropivacaine. A trial sequential analysis revealed that firm evidence was reached for the bupivacaine analysis but that a total of 1124 patients should be accumulated in order to avoid a type II error with ropivacaine. Of note, when ropivacaine, but not bupivacaine, is combined with dexamethasone during in vitro studies, crystallization may occur because of the elevated dexamethasone pH and the incompatibility of ropivacaine with alkaline solutions.<sup>30</sup> Perineural injection of this combination should therefore be cautioned, given the marginal clinical advantage over the systemic route and the 'off-label' nature of this route of administration. Systemic dexamethasone administration at moderate doses is therefore a recommended option that provides effective postoperative analgesia, associated with peripheral nerve block,<sup>31</sup> or not.<sup>8</sup>

There are notable limitations to this meta-analysis. First, despite a low risk of bias in the majority of included trials, and with the exception of moderate evidence for the primary outcome, the quality of evidence was low to very low. In addition, variation in the anaesthetic strategies used (i.v. sedation vs general anaesthesia vs spinal anaesthesia) or in the mixtures of local anaesthetics injected (long-acting vs combination of longand short-acting local anaesthetics, with or without epinephrine) may undermine the generalizability of our conclusions. Consequently, the existing literature would benefit from additional trials using a consistent methodology to provide better definition of the clinical benefit of perineural dexamethasone compared with systemic administration. In particular, study methodologies examining peripheral nerve block without additional general or neuraxial anaesthesia would strengthen conclusions with regard to pain scores and opioid consumption. Moreover, we were unable to draw any conclusions regarding the use of dexamethasone when combined with short- or intermediate-acting local anaesthetics, because no trials have investigated these mixtures.

In conclusion, there is moderate evidence that perineural dexamethasone combined with bupivacaine but not with ropivacaine slightly prolongs the duration of analgesia when compared with systemic dexamethasone, without an impact on the other secondary pain-related outcomes. The administration of dexamethasone in this setting should be balanced properly with recognition of the off-label indication of perineural administration and with consideration for the possibility of crystallization when combined with ropivacaine.

## Authors' contributions

Study design, literature search, statistical analysis, and manuscript preparation: E.A. Assessment of articles: A.J.-G., K.R.K., E.A. Data extraction: A.J.-G.

Primary manuscript preparation: M.B. Manuscript editing: K.R.K.

## Supplementary material

Supplementary material is available at British Journal of Anaesthesia online.

#### Acknowledgements

We are grateful to Mrs Isabelle von Kaenel (Head librarian, Lausanne University Hospital, Lausanne, Switzerland) for the assistance in the literature search and to Mrs Ann Bless for her assistance with the manuscript editing process.

## **Declaration of interest**

E.A. has received grants from the Swiss Academy for Anaesthesia Research (SACAR), Lausanne, Switzerland (no grant numbers attributed) and from B. Braun Medical AG, Sempach, Switzerland (no grant numbers attributed). E.A. has also received an honorarium from B. Braun Medical AG. All other authors declared no conflict of interest.

## Funding

Departmental funding (Department of Anaesthesia, Lausanne University Hospital, Lausanne, Switzerland). and Swiss Academy for Anaesthesia Research (SACAR, Lausanne, Switzerland).

## References

- Axelsson K, Gupta A. Local anaesthetic adjuvants: neuraxial versus peripheral nerve block. Curr Opin Anaesthesiol 2009; 22: 649–54
- Shrestha BR, Maharjan SK, Tabedar S. Supraclavicular brachial plexus block with and without dexamethasone - a comparative study. Kathmandu Univ Med J 2003; 1: 158–60
- Albrecht E, Kern C, Kirkham KR. Perineural vs intravenous administration of dexamethasone: more data are available. Br J Anaesth 2015; 114: 160

- Johansson A, Hao J, Sjölund B. Local corticosteroid application blocks transmission in normal nociceptive C-fibres. Acta Anaesthesiol Scand 1990; 34: 335–8
- Attardi B, Takimoto K, Gealy R, Severns C, Levitan ES. Glucocorticoid induced up-regulation of a pituitary K<sup>+</sup> channel mRNA in vitro and in vivo. Receptors Channels 1993; 1: 287–93
- Shishido H, Kikuchi S, Heckman H, Myers RR. Dexamethasone decreases blood flow in normal nerves and dorsal root ganglia. Spine 2002; 27: 581–6
- 7. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; **94**: 557–72
- De Oliveira GS, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology 2011; 115: 575–88
- 9. Desmet M, Braems H, Reynvoet M, *et al.* I.V. and perineural dexamethasone are equivalent in increasing the analgesic duration of a single-shot interscalene block with ropivacaine for shoulder surgery: a prospective, randomized, placebo-controlled study. *Br J Anaesth* 2013; **111**: 445–52
- 10. Kawanishi R, Yamamoto K, Tobetto Y, et al. Perineural but not systemic low-dose dexamethasone prolongs the duration of interscalene block with ropivacaine: a prospective randomized trial. Local Reg Anesth 2014; 7: 5–9
- Leurcharusmee P, Aliste J, Van Zundert TC, et al. A multicenter randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided infracla vicular block. Reg Anesth Pain Med 2016; 41: 328–33
- Albrecht E, Kern C, Kirkham KR. A systematic review and meta-analysis of perineural dexamethasone for peripheral nerve blocks. Anaesthesia 2015; 70: 71–83
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7: e1000251
- Baeriswyl M, Kirkham KR, Kern C, Albrecht E. The analgesic efficacy of ultrasound-guided transversus abdominis plane block in adult patients: a meta-analysis. Anesth Analg 2015; 121: 1640–54
- 15. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 2011; **343**: d5928.
- Collaboration TC. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from http://ims. cochrane.org/revman (accessed January 10, 2017)
- 17. Albrecht E, Guyen O, Jacot-Guillarmod A, Kirkham KR. The analgesic efficacy of local infiltration analgesia vs femoral nerve block after total knee arthroplasty: a systematic review and meta-analysis. Br J Anaesth 2016; 116: 597–609
- Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401–6
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58
- Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics 2000; 56: 455–63
- Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61: 64–75
- 22. Abdallah FW, Johnson J, Chan V, et al. Intravenous dexamethasone and perineural dexamethasone similarly prolong the duration of analgesia after supraclavicular brachial

plexus block: a randomized, triple-arm, double-blind, placebo-controlled trial. Reg Anesth Pain Med 2015; **40**: 125–32

- Aliste J, Leurcharusmee P, Engsusophon P, et al. A randomized comparison between intravenous and perineural dexamethasone for ultrasound-guided axillary block. Can J Anaesth 2017; 64: 29–36
- 24. Chun EH, Kim YJ, Woo JH. Which is your choice for prolonging the analgesic duration of single-shot interscalene brachial blocks for arthroscopic shoulder surgery? intravenous dexamethasone 5mg vs. perineural dexamethasone 5mg randomized, controlled, clinical trial. *Medicine* 2016; **95**: e3828
- 25. Dawson RL, McLeod DH, Koerber JP, Plummer JL, Dracopoulos GC. A randomised controlled trial of perineural vs intravenous dexamethasone for foot surgery. Anaesthesia 2016; 71: 285–90
- Fredrickson MJ, Danesh-Clough TK, White R. Adjuvant dexamethasone for bupivacaine sciatic and ankle blocks: results from 2 randomized placebo-controlled trials. *Reg Anesth Pain Med* 2013; 38: 300–7

- 27. Rahangdale R, Kendall MC, McCarthy RJ, et al. The effects of perineural versus intravenous dexamethasone on sciatic nerve blockade outcomes: a randomized, double-blind, placebo-controlled study. Anesth Analg 2014; **118**: 1113–9
- Rosenfeld DM, Ivancic MG, Hattrup SJ, et al. Perineural versus intravenous dexamethasone as adjuncts to local anaesthetic brachial plexus block for shoulder surgery. Anaesthesia 2016; 71: 380–8
- 29. YaDeau JT, Gordon MA, Goytizolo EA, et al. Buprenorphine, clonidine, dexamethasone, and ropivacaine for interscalene nerve blockade: a prospective, randomized, blinded, ropivacaine dose-response Study. Pain Med 2016; **17**: 940–60
- Watkins TW, Dupre S, Coucher JR. Ropivacaine and dexamethasone: a potentially dangerous combination for therapeutic pain injections. J Med Imaging Radiat Oncol 2015; 59: 571–7
- Desmet M, Vanneste B, Reynvoet M, et al. A randomised controlled trial of intravenous dexamethasone combined with interscalene brachial plexus blockade for shoulder surgery. *Anaesthesia* 2015; **70**: 1180–5

Handling editor: Jonathan Hardman